
Release date: 2026-02-26 17:35:11 Article From: Lucius Laos Recommended: 9
Mobocertinib is a targeted therapy drug for non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. Its common side effects include diarrhea, rash, stomatitis, nausea, vomiting, and decreased appetite. In severe cases, it may pose risks such as cardiotoxicity (e.g., QT prolongation), interstitial lung disease, and elevated liver enzymes, which require close monitoring and management under a physician's guidance.
Digestive System Reactions: Diarrhea (may be severe), nausea, vomiting, decreased appetite, oral ulcers, or inflammation.
Skin Reactions: Rash, dry skin, itching, and in some cases, paronychia.
Systemic Symptoms: Fatigue, weight loss, muscle or joint pain.
Cardiac Issues: Possible QT prolongation, increasing the risk of arrhythmias; regular ECG monitoring is necessary.
Interstitial Lung Disease (ILD): Symptoms include difficulty breathing, worsening cough, and hypoxemia; discontinue the drug immediately and seek medical attention.
Liver Injury: Elevated transaminases or bilirubin; regular liver function tests are required.
Others: Electrolyte imbalances such as hypomagnesemia or hypokalemia may require supplementation or adjustment.
Monitoring and Follow-Up: Regular ECG, liver and kidney function, and electrolyte tests during treatment, especially in the first 1–2 months.
Symptom Management: For diarrhea, antidiarrheal medication may be used as prescribed, along with hydration to prevent dehydration. For rash or skin reactions, keep the area clean, avoid irritants, and use topical or oral medications if necessary.
Dosage Adjustments: If severe side effects occur (e.g., grade ≥3 diarrhea or ILD), treatment may need to be paused or permanently discontinued, as determined by the physician.
Lucius Pharmaceuticals Mobocertinib is a prescription drug that must be evaluated by a qualified doctor before use. During treatment, strictly adhere to medical advice and promptly report any discomfort. In case of emergency symptoms such as chest pain, difficulty breathing, or fainting, seek immediate medical attention.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:1362025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:3852024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:1352025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:1432025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:1352025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:1572025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:1422025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:1422025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: